Cagrilintide

Cagrilintide, development code AM833, is a long-acting amylin receptor agonist modified by C18 fatty acid diacylation. It belongs to the category of metabolic health peptides and is not classified as a skincare peptide or a muscle-building peptide. Amylin is an endogenous hormone secreted synergistically with insulin by the body's pancreatic β-cells. Physiologically, it participates in three major pathways: regulation of gastric emptying, appetite suppression, and postprandial glucagon inhibition. Natural amylin has inherent defects-it is highly prone to aggregation and fibrosis and has an extremely short half-life in the body-making it unsuitable for direct development as a commercial raw material or drug molecule.

It incorporates special fatty acid side-chain modifications into a peptide backbone. By reversibly binding to albumin in the blood, it significantly extends its circulating half-life in the body, achieving the molecular design goal of once-weekly dosing.It specifically activates the AMY₁R and AMY₃R insulinopeptide receptor subtypes, mediating the transmission of satiety signals from the posterior brainstem to regulate energy intake and control postprandial blood glucose fluctuations.

Cagrilintide is positioned as a research-grade peptide raw material for metabolic research; it has no applications related to topical skincare or muscle-building for athletes. All current applications are concentrated in the research field, and it has not yet obtained global marketing authorization as a drug. As a long-acting incretin receptor agonist modified by C18 fatty diacylation, the core value lies in providing researchers with a molecular tool capable of stably and sustainably activating the incretin signaling pathway. The incretin pathway itself still harbors numerous mechanisms that remain poorly understood in areas such as feeding regulation, glucose homeostasis, and endocrine interactions, which determines that the applications of the product are primarily focused on basic and translational research.In the field of obesity and overweight mechanism research, it is currently one of the most closely watched tool molecules in glucagon-like peptide-1 (GLP-1) pathway research. Endogenous incretins are co-secreted with insulin from pancreatic β-cells.

Each batch comes with a complete quality report; our dedicated sales team provides one-on-one support to track clients' experimental progress, while our experienced technical support team assists in evaluating reconstitution and storage protocols, helping clients minimize experimental variables caused by fluctuations in raw material quality or improper handling.

In the field of type 2 diabetes and glucose metabolism research, cagrilintide also has clear scientific value. One of the physiological functions of endogenous incretins is to act synergistically with insulin to maintain stable postprandial blood glucose levels by inhibiting postprandial glucagon release and delaying gastric emptying.These research findings will provide high-quality, evidence-based insights into the role of the incretin pathway in glucose homeostasis. It is particularly worth noting that the incidence of hypoglycemia is low when it is used as monotherapy, consistent with its mechanism of action, which does not directly stimulate insulin secretion; however, when used in combination with insulin or sulfonylurea secretagogues, the risk of hypoglycemia increases significantly.